[{"id":"3bc05eae-3b84-41fb-9cd4-422462f86a5a","acronym":"KEYNOTE-D65","url":"https://clinicaltrials.gov/study/NCT05462236","created_at":"2022-07-18T14:01:41.581Z","updated_at":"2025-02-25T16:17:56.790Z","phase":"Phase 2","brief_title":"MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05462236 - KEYNOTE-D65","lead_sponsor":"AUM Biosciences Pte Ltd","biomarkers":" EGFR • HER-2 • BRAF • MSI • NTRK","pipe":" | ","alterations":" BRAF V600E • MSI-H/dMMR • BRAF V600","tags":["EGFR • HER-2 • BRAF • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • irinotecan • tinodasertib (AUM001)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-07-09"}]